Second-dose mRNA COVID-19 vaccine safety in patients with immediate reactions after the first dose: A case series

BACKGROUND: The rates of suspected allergic reactions to the first dose of the coronavirus disease 2019 (COVID-19) mRNA vaccines have been reported to be as high as 2%, with an anaphylaxis incidence up to 2.5 per 10,000 individuals. Anaphylaxis in response to the first dose may be considered a contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Iaboni, Aled, Jindal, Nina, Betschel, Stephen D., Song, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010013/
https://www.ncbi.nlm.nih.gov/pubmed/36203478
http://dx.doi.org/10.1016/j.jacig.2022.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010013/
https://www.ncbi.nlm.nih.gov/pubmed/36203478
http://dx.doi.org/10.1016/j.jacig.2022.03.003

Ejemplares similares